Lori Lawley

Director of Finance/CFO at LUMOS PHARMA, INC.

Net worth: 35 287 $ as of 2024-03-30

40 year

Commercial Services

Health Technology

Consumer Services

Lori Lawley active positions

Companies	Position	Start	End
LUMOS PHARMA, INC.	Corporate Secretary	2020-02-29	-
	Director of Finance/CFO	2021-07-03	-
	Comptroller/Controller/Auditor	2020-02-29	-

Companies	Position	Start	End
LUMOS PHARMA, INC.	Comptroller/Controller/Auditor	2018-07-25	2020-02-29
Ernst & Young LLP Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.	Corporate Officer/Principal	2014-09-30	2015-03-31

McCombs School of Business

Graduate Degree

International

Operational

Comptroller/Controller/Auditor	2
Director of Finance/CFO	1
Corporate Secretary	1

Sectoral

Positions held

Active

Inactive

Listed companies

Private companies

Private companies	3
Ernst & Young LLP Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.	Commercial Services
NewLink Genetics Corp. NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.	Health Technology
Lumos Pharma, Inc.